Applied BioCode Total Liabilities
Applied BioCode total liabilities. Based on the latest financial reports, Applied BioCode (6598) has total liabilities worth NT$343.23 Million TWD (≈ $10.81 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Applied BioCode liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Applied BioCode (2012–2024)
Total liabilities of Applied BioCode from 2012 to 2024. This chart illustrates how Applied BioCode's total liabilities have evolved over time, based on quarterly financial data.
Applied BioCode Competitors by Total Liabilities
The table below lists competitors of Applied BioCode ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Putian Telecommunications Co Ltd Class B
SHE:200468
|
China | HK$566.28 Million |
|
Spyrosoft Spólka Akcyjna
F:2NP
|
Germany | €89.73 Million |
|
Infant Bacterial Therapeutics AB (publ)
ST:IBT-B
|
Sweden | Skr53.87 Million |
|
Fifth District Bancorp, Inc. Common Stock
NASDAQ:FDSB
|
USA | $403.12 Million |
|
Nabaltec AG
F:NTG
|
Germany | €147.39 Million |
|
DeviceENG.CO.Ltd
KQ:187870
|
Korea | ₩65.68 Billion |
|
Western Asset Investment Grade Defined Opportunity Closed Fund
NYSE:IGI
|
USA | $2.75 Million |
|
Lanvin Group Holdings Limited
NYSE:LANV
|
USA | $693.10 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Applied BioCode's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Applied BioCode assets under control.
Liquidity & Leverage Metrics
Applied BioCode Total Liabilities Ratios Explained
Applied BioCode total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Applied BioCode's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Applied BioCode (2012–2024)
The table below shows the annual total liabilities of Applied BioCode from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$336.07 Million ≈ $10.59 Million |
+1.16% |
| 2023-12-31 | NT$332.22 Million ≈ $10.47 Million |
-16.19% |
| 2022-12-31 | NT$396.38 Million ≈ $12.49 Million |
+241.68% |
| 2021-12-31 | NT$116.01 Million ≈ $3.65 Million |
-17.27% |
| 2020-12-31 | NT$140.23 Million ≈ $4.42 Million |
-25.55% |
| 2019-12-31 | NT$188.36 Million ≈ $5.93 Million |
+131.55% |
| 2018-12-31 | NT$81.35 Million ≈ $2.56 Million |
+34.89% |
| 2017-12-31 | NT$60.30 Million ≈ $1.90 Million |
+17.84% |
| 2016-12-31 | NT$51.17 Million ≈ $1.61 Million |
+25.81% |
| 2015-12-31 | NT$40.67 Million ≈ $1.28 Million |
+4.37% |
| 2014-12-31 | NT$38.97 Million ≈ $1.23 Million |
+64.93% |
| 2013-12-31 | NT$23.63 Million ≈ $744.47K |
+18.18% |
| 2012-12-31 | NT$20.00 Million ≈ $629.95K |
-- |
About Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more